Inceptionr LLC Increases Holdings in Natera, Inc. $NTRA

Inceptionr LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 51.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 6,868 shares of the medical research company’s stock after buying an additional 2,344 shares during the quarter. Inceptionr LLC’s holdings in Natera were worth $1,160,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in NTRA. Price T Rowe Associates Inc. MD lifted its stake in Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares during the period. JPMorgan Chase & Co. increased its position in Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after purchasing an additional 3,263,822 shares during the period. Nuveen LLC bought a new position in Natera in the 1st quarter worth $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after purchasing an additional 732,156 shares during the period. Finally, Ninety One UK Ltd lifted its position in shares of Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after purchasing an additional 336,985 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Performance

Shares of NTRA stock opened at $237.12 on Thursday. The company has a market capitalization of $32.72 billion, a price-to-earnings ratio of -103.55 and a beta of 1.75. Natera, Inc. has a one year low of $125.38 and a one year high of $241.28. The company’s 50-day moving average is $190.07 and its 200 day moving average is $169.57.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the prior year, the company posted ($0.26) EPS. The company’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NTRA. UBS Group upped their target price on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Piper Sandler lifted their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI upped their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. BTIG Research raised their price objective on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, Barclays boosted their target price on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $220.88.

Insiders Place Their Bets

In other news, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the transaction, the director directly owned 1,154,198 shares of the company’s stock, valued at $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the completion of the sale, the chief executive officer owned 144,816 shares of the company’s stock, valued at $28,957,407.36. The trade was a 52.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 308,366 shares of company stock valued at $63,050,068. Insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.